StabiLux’s innovation uses nano-technology to completely change imaging resolution.

Go to Market Strategy:
StabiLux® primarily plans to manufacture and sell dyes to leading reagent producers such as BD, Bio-Legends, Beckman Coulter, and MilliporeSigma. Since our technology can be adapted to any reagent, we offer them an opportunity to enhance/improve their entire product catalog.

Financial Projection:
The company is seeking outside investment as well as strategic partnerships. We are currently raising $3.0M Series A. Funds will be used for product launch and expansion, scale, and additional IP filing. The company has raised 2.7M to date with $1.7M in grants and other non-dilutive funding.  Additional grant funding has also been received or pending.

Intellectual Property: 
A foundational patent was filed and a broad range of patent protection has been submitted. Broad PCT coverage and broad-based US filing.

IMAGING PLATFORM WITH OUTSTANDING RETURN POTENTIAL

• Platform can be used with any organic dye.
• Technology can be used for imaging on the cell, inside cells, and messages between cells.
• Allows reagent producers to update their entire product line.
• Imaging based. Starts with flow cytometry, but can grow in the future for use in ELISA, confocal microscopy, surgical imaging, clinical use…and more.

WITH REDUCED INVESTMENT RISK AND TIMELINE

• 5 years of development
• Samples shipped to leading industry partners
• Sales of first product underway
• Operations up and running in Ann Arbor MI and Houghton MI
• Numerous patent filings and broad protection

We welcome opportunities to collaborate with bioscience and biomedical companies that wish to take advantage of our platform nanoparticle technology.

If you are interested in exploring investment or partnership opportunities with StabiLux Biosciences®, Inc, please contact:

Steve Tokarz, MBA
CEO
stevetokarz1@stabiluxbiosciences.com